Intensity Therapeutics Inc. has announced the presentation of two posters at the 2025 San Antonio Breast Cancer Symposium (SABCS). The first poster, PS5-08-16, reports early observations from the INVINCIBLE-4 study, an ongoing randomized Phase 2 clinical trial investigating INT230-6 in combination with standard of care $(SOC)$ neoadjuvant immunochemotherapy in patients with early-stage triple negative breast cancer (TNBC). Preliminary data indicate that the INT230-6 cohort experienced 50% fewer grade 3 or higher adverse events compared to the SOC-alone cohort. Fourteen patients have been treated to date, with safety data for those receiving INT230-6 plus SOC remaining favorable. These results are being presented at the symposium. A second poster, PS4-10-15, outlines a potential Phase 3 clinical study design evaluating INT230-6 plus SOC, with and without the anthracycline doxorubicin, for breast cancer treatment. This presentation also takes place at the SABCS.